CARLSBAD, Calif.--(BUSINESS WIRE)--June 27, 2006--The Immune Response Corporation (OTCBB:IMNR - News) announced today the development of a serum-free, chemically defined cell culture medium for the production of HIV-1 from HUT-78 cells, a human T-cell lymphoma cell line. A poster on the medium optimization process is being presented this week at the Vaccine Technology conference in Puerto Vallarta, Mexico. This conference is being held June 25th-30th, and is a biopharmaceutical development and manufacturing event with a special emphasis on HIV vaccine candidates and other global vaccines. The development of this medium is an important step in the development of a vaccine utilizing whole-inactivated HIV to stimulate the human immune system against the virus. The Immune Response Corporation is currently evaluating this approach for a therapeutic vaccine in clinical trials of its second-generation HIV immunotherapy IR103. This technology will also be utilized toward the development of a preventive vaccine candidate.
